ライフサイエンスコーパス: adrenergic agonist

1 ications (opioids, vasopressors, and alpha-2 adrenergic agonists).

2 ncreased metabolic responsiveness to a beta3-adrenergic agonist.

3 l nerve block or spinal clonidine, an alpha2-adrenergic agonist.

4 ncrease by a standard inhaled dose of a beta-adrenergic agonist.

5 reased as a function of the concentration of adrenergic agonist.

6 g by cold exposure or treatment with a beta3-adrenergic agonist.

7 gnaling in response to injection of a beta-3 adrenergic agonist.

8 responses to electrical stimulation or to an adrenergic agonist.

9 measured from gland fragments in response to adrenergic agonists.

10 ts inhibitory effect can be reversed by beta-adrenergic agonists.

11 ystem auditory response properties by NE and adrenergic agonists.

12 dulation of TRPM7 activity by muscarinic and adrenergic agonists.

13 the acetylcholine receptor ion channel, and adrenergic agonists.

14 or the increase in heart rate caused by beta-adrenergic agonists.

15 Stimulated release was inhibited by alpha(2)-adrenergic agonists.

16 responds to low doses of cholinergic or beta-adrenergic agonists.

17 ectorial fluid transport in response to beta-adrenergic agonists.

18 egulating portal vein responsiveness to beta-adrenergic agonists.

19 of LTP also is modulated importantly by beta-adrenergic agonists.

20 ts of clonidine and other sympathoinhibitory adrenergic agonists.

21 s anesthetic depth in the presence of alpha2-adrenergic agonists.

22 e in white adipose tissue stimulated by beta-adrenergic agonists.

23 nses to glutamatergic, lysophosphatidic, and adrenergic agonists.

24 e nucleotide-sensitive binding of the alpha2-adrenergic agonist, [3H]UK-14,304.

25 kers, 4.01 (CrI, 0.48 to 7.43); 1995: alpha2-adrenergic agonists, 5.64 (CrI, 1.73 to 9.50); 1999: pro

26 ly relevant airspace concentrations of beta2-adrenergic agonists a) stimulate maximal cAMP-dependent

27 this review the authors will focus on alpha2-adrenergic agonists, a new class of sedative/analgesic a

28 beta-Adrenergic agonists accelerate the clearance of alveolar

29 Our findings suggest that alpha2-adrenergic agonists act via a Gi family member on early

30 nary resuscitation were traced to the alpha1-adrenergic agonist action of epinephrine.

31 dolol exhibits approximately 60% of the beta-adrenergic agonist activity of xamoterol in normal human

32 , high Ca(2+), lysophosphatidylcholine, beta-adrenergic agonist, acylcarnitine, and the Ca(2+) ionoph

33 We have previously shown that beta-adrenergic agonists affect Na+-K+ pump current (Ip) thro

34 ings of increased risk associated with beta2-adrenergic agonist agents together with stress related t

35 ta-blockers was less common but use of beta2-adrenergic agonist agents was more common in patients wi

36 proterenol, a rapidly acting peripheral beta-adrenergic agonist akin to adrenaline, or saline.

37 the present study, we show that the alpha(2)-adrenergic agonist (alpha(2)-agonist) clonidine induced

38 nvestigate the effects of a selective alpha2-adrenergic agonist, alpha-methylnorepinephrine (alphaMNE

39 The selective alpha2-adrenergic agonist, alphaMNE, was as effective as epinep

40 Alpha2-adrenergic agonists also reduced stimulation of ERK1/2 b

41 Isoproterenol, the beta-adrenergic agonist, also elicited protein secretion at 1

42 We examined the effect of beta-adrenergic agonists and antagonists on action potential

43 inding protein (beta ARB) is induced by beta-adrenergic agonists and binds to G-protein-linked recept

44 se activation and cFos expression induced by adrenergic agonists and biomechanical stress.

45 ysfunction, which can be prevented with beta-adrenergic agonists and cAMP.

46 In contrast, alpha(1D)-adrenergic agonists and EGF do not use Pyk2 and Src but

47 cient mice, the contractile response to beta-adrenergic agonists and extracellular calcium is reduced

48 uller cells are unique in response to alpha2-adrenergic agonists and imply a role for Muller cells in

49 Both beta-adrenergic agonists and insulin provoke sequestration of

50 and regulate other cellular functions, beta-adrenergic agonists and nitric oxide-containing compound

51 r smooth muscle to block the effect of alpha-adrenergic agonists and reduce vascular tone.

52 inhibitory compounds, clonidine (an alpha-2 adrenergic agonist) and muscimol (a GABAa agonist) induc

53 ouse hearts exposed to isoproterenol, a beta-adrenergic agonist, and isoproterenol-induced increases

54 10(-4) M phenylephrine, a selective alpha 1-adrenergic agonist, and then treated with 10(-4) M furos

55 nhaled corticosteroids with long-acting beta-adrenergic agonists, and anti-IgE.

56 the rodent, by factors such as insulin, beta-adrenergic agonists, and glucocorticoids (GCs).

57 nction measurements, responsiveness to beta2-adrenergic agonists, and health care use.

58 ction abnormalities, diminished responses to adrenergic agonists, and impaired ventricular function o

59 hemodynamic responses to bolus injections of adrenergic agonists, and intrinsic heart rate were deter

60 ponse to adenosine, prostaglandin E(2), beta-adrenergic agonists, and other mediators, is a means of

61 c anhydrase inhibitors, beta-blockers, alpha-adrenergic agonists, and prostaglandin analogues on opti

62 Inhaled beta-adrenergic agonists are the most commonly used medicatio

63 Caffeine and beta-adrenergic agonists are well-recognised drugs that cause

64 Vascular responses to adrenergic agonists as well as endothelial dilator funct

65 dation was administered with DEX, an alpha-2 adrenergic agonist, as an intravenous bolus (2 mug per k

66 s system (SNS) and can be stimulated by beta-adrenergic agonists, at least in animals.

67 hite)) were administered Ractopamine (a beta-adrenergic agonist; BA; 20 ppm in feed) or Reporcin (rec

68 rs, a febrile state, vagotonic agents, alpha-adrenergic agonists, beta-adrenergic blockers, tricyclic

69 (Thy1-CFP mice) to determine how the alpha2-adrenergic agonist brimonidine influences loss of Thy1 p

70 Administration of beta-adrenergic agonist bronchodilators to patients with airw

71 The most promising solutions are the alpha-2-adrenergic agonists but further investigation is necessa

72 ered a Frizzled-2 chimera responsive to beta-adrenergic agonist by using the ligand-binding domains o

73 e computed bias factors for a number of beta-adrenergic agonists by comparing BRET assays of receptor

74 ttenuate responses of cardiomyocytes to beta-adrenergic agonists by decreasing PLN phosphorylation an

75 -term use of decongestant nasal spray (alpha adrenergic agonist) causes nasal congestion by rhinitis

76 Dexmedetomidine, an alpha-2-adrenergic agonist, causes a unique kind of sedation, ac

77 The beta(3)-adrenergic agonist CL 316,243 (CL) increased lipolysis a

78 weight in response to treatment with a beta3-adrenergic agonist (CL 316,243).

79 ice, as were the effects of fasting, a beta3-adrenergic agonist (CL316243), and thyroid hormone on th

80 e curves for metabolic response to a beta(3)-adrenergic agonist, CL316243, indicating normal sensitiv

81 ze reverse remodeling, followed by the beta2 adrenergic agonist clenbuterol.

82 therefore examined the effects of the alpha2-adrenergic agonist clonidine on mean arterial pressure,

83 actions were evoked by the selective alpha2 adrenergic agonist clonidine.

84 In contrast, the adrenergic agonists clonidine or norepinephrine, and the

85 phenylephrine (PHE; 0.5 mg/kg BW), an alpha2-adrenergic agonist, clonidine (CLON; 0.6 mg/kg BW), or a

86 when administered together with the alpha-2 adrenergic agonist, clonidine.

87 ding leukotriene modifiers, long-acting beta-adrenergic agonists, combination inhaled corticosteroids

88 which corticosteroids and long-acting beta2 -adrenergic agonists confer protection against pathologic

89 renergic receptors because a specific alpha2-adrenergic agonist could substitute for epinephrine in p

90 We studied whether beta-adrenergic agonists could restore lung edema clearance i

91 sts regulate their proliferation, and a beta-adrenergic agonist decreases bone mass in leptin-deficie

92 Conversely, administering a beta2-adrenergic agonist decreases GVHD in mice housed at 30 d

93 ct of tyramine, and increased sensitivity to adrenergic agonists demonstrate dramatically disordered

94 The alpha-2 adrenergic agonist dexmedetomidine (Dex), 3-300 microg/k

95 nd to describe the application of an alpha-2-adrenergic agonist dexmedetomidine in the anesthetic man

96 ams, 3 or 30 nmol of phenylephrine (alpha(1)-adrenergic agonist) did not alter bladder activity; wher

97 ent of A-ZIP/F-1 mice with CL316243, a beta3-adrenergic agonist, did not increase O2 consumption.

98 The beta-adrenergic agonist dobutamine was infused via a peripher

99 s but was normalized with supply of the beta-adrenergic agonist dobutamine.

100 Two clinically relevant beta-adrenergic agonists, dopamine (beta-1 agonist) and dobut

101 Together, our data reveal a new paradigm for adrenergic agonist dose-dependent cAMP/PKA activities fo

102 azolidines including analogues of the alpha2 adrenergic agonist drug clonidine is elaborated.

103 Altered vascular responses to adrenergic agonists during pregnancy are thought to play

104 stimuli in rat myocytes, including alpha(1)-adrenergic agonists, endothelin-1, prostaglandin F(2alph

105 Further, administration of a beta(2) adrenergic agonist enhances mobilization in both control

106 The beta-adrenergic agonist failed to elicit a significant number

107 Isoproterenol (beta-adrenergic agonist) failed to alter plasma leptin but re

108 of either low or high doses of the alpha-2A adrenergic agonist guanfacine (GFC) to aged monkeys has

109 oxetine than for the extended-release alpha2-adrenergic agonists guanfacine or clonidine (no studies)

110 We examine the effects of the alpha2 adrenergic agonist, guanfacine HCl, on responses to stre

111 beta-Adrenergic agonists have been selected as model compound

112 Alpha-2 adrenergic agonists have been useful as adjuvant for reg

113 Alpha2-adrenergic agonists have specific and selective effects

114 eatments of inhaled corticosteroids and beta-adrenergic agonists; however, 5-10% have severe disease

115 for treating hypertension over pure alpha(2)-adrenergic agonists (i.e., guanabenz) due to its lowered

116 dies are required to determine whether beta2-adrenergic agonists improve outcome in patients with acu

117 factor-alpha (TNF) as well as to an alpha(2)-adrenergic agonist in an area of the central nervous sys

118 The modulation of the exchanger by a beta-adrenergic agonist in whole-cell clamped ventricular myo

119 f peripheral blood mononuclear cells to beta-adrenergic agonists in patients with heart failure (HF)

120 tested a panel of combinations of opioid and adrenergic agonists in PKCepsilon knock-out mice and fou

121 Following fasting or injection of a beta3-adrenergic agonist, in vivo lipolysis and ketogenesis we

122 beta-adrenergic agonists increase active Na(+) transport and

123 Beta-adrenergic agonists increase ATPase activity through an

124 We have also previously shown that alpha-adrenergic agonists increase Ip through a protein kinase

125 adrenergic antagonists, indicating that beta-adrenergic agonists increase the metabolism of BAT.

126 Both alpha1- and beta-adrenergic agonists increase the severity of global myoc

127 The data suggest that beta-adrenergic agonists increased alveolar fluid reabsorptio

128 d in cultured cardiac fibroblasts by several adrenergic agonists, indicating that the adrenergic axis

129 Beta-adrenergic agonists induce protein kinase A (PKA) phosph

130 Phenylephrine (100 mumol/L), an alpha1 adrenergic agonist, induced upregulation of Nox4 (1.5-fo

131 n I (cTnI) contributes significantly to beta-adrenergic agonist-induced acceleration of myocardial re

132 duced activation of ERKs requires Raf, alpha-adrenergic agonist-induced activation of ERKs does not r

133 otein, is required for endothelin- and alpha-adrenergic agonist-induced cardiomyocyte hypertrophy and

134 alpha(1)-adrenergic agonist-induced hypertrophy of cardiac myocyt

135 and imply a role for Muller cells in alpha2-adrenergic agonist-induced photoreceptor protection.

136 to the lacrimal gland inhibited neurally and adrenergic agonist-induced protein secretion by 77% and

137 production by 52% and inhibited neurally and adrenergic agonist-induced protein secretion by 80% and

138 cks L-LTP; conversely, application of a beta-adrenergic agonist induces the L-LTP.

139 tent, highly specific, and long-acting beta2-adrenergic agonist, induces renal mitochondrial biogenes

140 aneous firing rate, and clonidine-an alpha2A-adrenergic agonist-inhibited LC neuronal firing less eff

141 Alpha-adrenergic agonists injected into the RVM produce change

142 etomidine (Dex), a potent, selective alpha-2 adrenergic agonist, injected bilaterally directly into t

143 ne temperature was seen before or after beta-adrenergic agonist injection.

144 In combination with beta-adrenergic agonists, insulin stimulates internalization

145 uggest that vascular responsiveness to alpha-adrenergic agonists is maintained during postexercise hy

146 mylase secretion from parotid glands by beta-adrenergic agonists is mediated by the activation of ade

147 Dexmedetomidine, an alpha2 adrenergic agonist, is a useful sedative but can also ca

148 Additional administration of the beta-adrenergic agonist isoprenaline (1 microM) or the membra

149 The beta-adrenergic agonist isoprenaline (10 microM) also activat

150 esponses, the sensitivity of ICa to the beta-adrenergic agonist isoprenaline (Iso) was studied in bot

151 ed the Ca(2+) current stimulated by the beta-adrenergic agonist isoprenaline (Iso), and washout of AC

152 We show that the adrenergic agonist isoprenaline promotes receptor and G

153 ogenic index, 4.10; n = 8 cells) or the beta-adrenergic agonist isoproterenol (arrhythmogenic index,

154 lipolysis in response to 10 muM of the beta-adrenergic agonist isoproterenol (by 42%), 10 muM of the

155 reshold concentration (1 nmol/L) of the beta-adrenergic agonist isoproterenol (Iso), genistein caused

156 ity of the Cl- current to the selective beta-adrenergic agonist isoproterenol (Iso), which indicates

157 with glucagon but not by that with the beta2-adrenergic agonist isoproterenol (ISO).

158 The beta-adrenergic agonist isoproterenol (ISO; 1 muM) increased

159 n the pipette or in the presence of the beta-adrenergic agonist isoproterenol (isoprenaline; ISO).

160 Using the beta-adrenergic agonist isoproterenol as a specific pathologi

161 egrated syncytium was responsive to the beta-adrenergic agonist isoproterenol as well as to other pha

162 For comparison, the beta-adrenergic agonist isoproterenol caused a 38 % increase

163 membrane induced by cholera toxin, the beta-adrenergic agonist isoproterenol caused a rapid partial

164 on of noradrenaline or of the selective beta-adrenergic agonist isoproterenol decreased gap junction-

165 hallenge of Zmpste24(-/-) mice with the beta-adrenergic agonist isoproterenol did not trigger ventric

166 The beta-adrenergic agonist isoproterenol failed to increase Ca2+

167 The beta-adrenergic agonist isoproterenol increased lung liquid c

168 Here, we found that the beta-adrenergic agonist isoproterenol induced mature beta-adr

169 uce LTP, but the addition of either the beta-adrenergic agonist isoproterenol or the cAMP analog 8-br

170 In both rat and human strips, the full beta-adrenergic agonist isoproterenol raised cAMP levels by >

171 Stimulation of LQT2 cells with beta-adrenergic agonist isoproterenol resulted in prolongatio

172 Membrane-permeable 8-bromo-cAMP and the beta-adrenergic agonist isoproterenol significantly reversed

173 ing the chimera (beta2AR-Rfz1) with the beta-adrenergic agonist isoproterenol stimulated stabilizatio

174 els (including PGE2, forskolin, and the beta-adrenergic agonist isoproterenol) can inhibit P2Y recept

175 ptic stimulation in the presence of the beta-adrenergic agonist isoproterenol, a combination that ind

176 initiating rapid endocytosis of B2ARs by the adrenergic agonist isoproterenol, we observed bright "pu

177 ates the vasorelaxation response to the beta-adrenergic agonist isoproterenol, without affecting endo

178 a-adrenergic blocker metoprolol and the beta-adrenergic agonist isoproterenol.

179 ose-dependent inotropic response to the beta-adrenergic agonist isoproterenol.

180 ed to describe myocyte responses to the beta-adrenergic agonist isoproterenol.

181 ted the Mg(2+) extrusion induced by the beta-adrenergic agonist isoproterenol.

182 levels that were pre-elevated with the beta-adrenergic agonist isoproterenol.

183 ts caused by high concentrations of the beta-adrenergic agonist isoproterenol.

184 it was blocked in cells pretreated with beta-adrenergic agonist isoproterenol.

185 myocytes following stimulation with the beta-adrenergic agonist isoproterenol.

186 Intraperitoneal injection of a beta-adrenergic agonist (isoproterenol) enhances SIRT2 expres

187 n VSMC as profoundly as the G(s)-linked beta-adrenergic agonist, isoproterenol (ISO), but in a transi

188 t, clonidine (CLON; 0.6 mg/kg BW), or a beta-adrenergic agonist, isoproterenol (ISO; 0.2 mg/kg BW) al

189 s PKA activities at the SR induced by a beta-adrenergic agonist, isoproterenol, and subsequently bloc

190 Pretreatment with a beta-adrenergic agonist, isoproterenol, or a cAMP analog amel

191 activated by parathyroid hormone or the beta-adrenergic agonist, isoproterenol.

192 attenuated contractile responses to the beta-adrenergic agonist, isoproterenol.

193 amount of high affinity binding of the beta-adrenergic agonist, isoproterenol.

194 Apical adrenergic agonists, isoproterenol and epinephrine (10(-

195 tion stimulated by cholinergic and alpha(1D)-adrenergic agonists, it does not play a role in epiderma

196 A beta3-adrenergic agonist known to activate metabolic heat prod

197 shown that combinations of long-acting beta2-adrenergic agonists (LABAs) and long-acting muscarinic a

198 Stimulation with 2 adrenergic agonists led to sudden cardiac death of all m

199 n inhaled corticosteroid/long-acting beta(2)-adrenergic agonist medications in African American asthm

200 The alpha1-adrenergic agonist methoxamine increased NKCC1 activity

201 lpha1 was reversed with the selective alpha1-adrenergic agonist midodrine, the inappropriate heat los

202 The adrenergic agonists norepinephrine and phenylephrine ind

203 A beta(1)-adrenergic agonist, norepinephrine (10(-9)-10(-6) m), in

204 s study evaluated the effect of various beta-adrenergic agonists on (18)F-FDG uptake in brown adipose

205 o investigate the actions of alpha- and beta-adrenergic agonists on Na+-K+ pump current.

206 c peptide (ANP) can attenuate the effects of adrenergic agonists on the growth of cardiac myocytes an

207 his work were to study the effects of alpha2-adrenergic agonists on the inflammatory response in vivo

208 cts of ephedrine sulfate, an alpha- and beta-adrenergic agonist, on subjective and physiological sexu

209 state was observed after treatment with beta-adrenergic agonist or with coexpression of phosphomimeti

210 cyte secretion in response to secretin, beta-adrenergic agonists, or changes in [HCO(3)(-)](i), respe

211 the 2-(substituted-benzyl)imidazoline alpha-adrenergic agonist oxymetazoline (8) binds with high aff

212 An adrenergic agonist, para-aminoclonidine, inhibited forsk

213 gonist carbachol (10(-4) M), or the alpha(1)-adrenergic agonist phenylephrine (10(-4) M), and peroxid

214 myocytes treated for 48 h with the alpha(1)-adrenergic agonist phenylephrine (PE) had an 80% increas

215 cations (separated by 5 min) of the alpha(1)-adrenergic agonist phenylephrine (PE) in combination wit

216 The alpha-adrenergic agonist phenylephrine (PE) increased tissue s

217 sfected HepG2 cells (TFG2) with the alpha(1)-adrenergic agonist phenylephrine (PE) significantly acti

218 The alpha(1)-adrenergic agonist phenylephrine (PE; 100 micrometer) al

219 Administration of the alpha1-adrenergic agonist phenylephrine did not constrict isola

220 The selective alpha1 adrenergic agonist phenylephrine had no effect on membra

221 The adrenergic agonist phenylephrine increased instantaneous

222 Moreover, infusions of the selective alpha1 adrenergic agonist phenylephrine into the basal forebrai

223 In contrast, contractions to the alpha1-adrenergic agonist phenylephrine or the thromboxane (TX)

224 sed in a dose-dependent manner by the alpha1-adrenergic agonist phenylephrine, and this increase is b

225 cholinergic agonist carbachol, the alpha(1D)-adrenergic agonist phenylephrine, or EGF.

226 > 0.05) during local administration of alpha-adrenergic agonists (phenylephrine (PE), alpha(1); cloni

227 cts of angiotensin II (Ang II) and the alpha-adrenergic agonist, phenylephrine (PE), on cardiac energ

228 n animals were treated with either an alpha1-adrenergic agonist, phenylephrine (PHE; 0.5 mg/kg BW), a

229 erm intravenous administration of an alpha-1 adrenergic agonist, phenylephrine, and a beta-1 adrenerg

230 reas treatment of hepatocytes with an alpha1 adrenergic agonist, phenylephrine, enhanced hepatocyte p

231 yocytes from GRK5-knockout (KO) mice to beta-adrenergic agonists, pretreatment of GRK5-KO cardiomyocy

232 We have found that alpha-2 adrenergic agonists prevent the PC/RS neurotoxic side ef

233 These studies indicate that cAMP and beta-adrenergic agonists produce distinct short and long term

234 Dexmedetomidine, an alpha2-adrenergic agonist, produces sedation and reduces volati

235 eatment with xylazine or UK14304, two alpha2-adrenergic agonists, reduced neutrophil migration by 60%

236 modulation of the hypnotic effect of alpha-2 adrenergic agonists remains uncertain.

237 suggest that the suppressive effect of beta-adrenergic agonists requires the presence of the P-loop

238 Administration of beta-adrenergic agonist restored the expression of presynapti

239 Beta-adrenergic agonists restored AFR in rats exposed to 8% O

240 re small and insensitive to insulin and beta-adrenergic agonists resulting in reduced adipocyte lipid

241 because intra-hippocampal injections of beta-adrenergic agonists reversed cell death.

242 dicate that systemically administered alpha2-adrenergic agonists selectively activate ERKs in retinal

243 Dose-response curves for both adrenergic agonists showed that HC increased linearly as

244 proterenol, a rapidly acting peripheral beta-adrenergic agonist similar to adrenaline, to induce sens

245 travenous infusions of isoproterenol, a beta-adrenergic agonist similar to adrenaline.

246 Beta-adrenergic agonists stimulate cardiac contractility and

247 alpha(1D)-Adrenergic agonists stimulate eNOS to produce NO, leadin

248 mine and metaraminol, three selective alpha1-adrenergic agonists, stimulate Ip in a similar manner to

249 el role for TGF-beta1 in impairing the beta- adrenergic agonist-stimulated alveolar fluid clearance i

250 lates both peripheral vascular tone and beta-adrenergic agonist-stimulated cardiac contractility, pre

251 ulated above basal secretion, whereas alpha1-adrenergic-agonist-stimulated protein secretion was incr

252 action by which phenylephrine, an alpha(1) -adrenergic agonist stimulating intracellular D-myo-inosi

253 Although it is well known that beta-adrenergic agonist stimulation increases alveolar epithe

254 ed basal lipolysis that is resistant to beta-adrenergic agonist stimulation, and are cold-sensitive e

255 asured in response to cholinergic and alpha1-adrenergic agonist stimulation.

256 Intrathecal administration of alpha(2) adrenergic agonists, such as clonidine, is capable of al

257 The beta-adrenergic agonist terbutaline produced changes in AQP5

258 ial cells were treated with cAMP or the beta-adrenergic agonist terbutaline, a biphasic AQP5 response

259 Reaction of the medically relevant alpha-adrenergic agonists tetrahydrozoline and idazoxan produc

260 cell stimulation with isoproterenol, a beta-adrenergic agonist that activates adenylyl cyclase, enha

261 application of isoproterenol (1 muM), a beta-adrenergic agonist that activates PKA, significantly red

262 e efficacy of midodrine, a selective alpha-1 adrenergic agonist that decreases venous capacitance, in

263 0-minute infusion of phenylephrine, an alpha-adrenergic agonist that enhances PKC activity, produced

264 Clonidine is a partial alpha 2 adrenergic agonist that has a variety of different actio

265 fter administration of isoproterenol, a beta-adrenergic agonist that increases circulating levels of

266 ntly, 3OST2 transcription is blocked by beta-adrenergic agonists that activate the pineal melatonin f

267 Pharmacological treatment with a beta-adrenergic agonist to stimulate lipolysis evoked a 3-fol

268 nervation of the gland nor the ability of an adrenergic agonist to stimulate NAT activity was reduced

269 ase pathway, attenuating the ability of beta-adrenergic agonists to act following stimulation of cell

270 posure to cognitive novelty and/or oral beta-adrenergic agonists to lessen the effects of Abeta accum

271 specific impairment in the capacity of beta2-adrenergic agonists to promote lipolysis in subcutaneous

272 both beta(3)-selective and nonspecific beta-adrenergic agonists to stimulate lipolysis is markedly c

273 ays the effects of chronic exposure to beta3-adrenergic agonist treatment, which also results in impr

274 The stimulation of lipolysis by beta-adrenergic agonists triggers rapid phosphorylation of pe

275 ial hindlimb infusion of the specific alpha2-adrenergic agonist UK 14,304 during KATP channel activat

276 similar sensitivity to the specific alpha(2)-adrenergic agonist UK 14,304, to serotonin, and to angio

277 ole and mechanisms of action of the alpha(2)-adrenergic agonist UK14,304 in the regulation of growth

278 Epinephrine and the selective alpha2-adrenergic agonist UK14304 reduced insulin secretion and

279 and torsade de pointes (TdP) induced by beta-adrenergic agonists under conditions mimicking the LQT1

280 as relevant in the context of detecting beta-adrenergic agonists use in animals.

281 ing promotes anti-nociception, with alpha(2)-adrenergic agonists used clinically.

282 With continuous exposure to beta2-adrenergic agonists, vascular tissue becomes desensitize

283 s by its alpha1 (alpha1) and alpha2 (alpha2)-adrenergic agonist vasopressor actions.

284 A beta3 adrenergic agonist was administered for 2 weeks in Wista

285 ion stimulated by phenylephrine, an alpha(1)-adrenergic agonist, was measured with a fluorescence ass

286 ctural similarities of NNK with classic beta-adrenergic agonists, we tested the hypothesis that NNK s

287 parameters and inotropic response to a beta-adrenergic agonist were measured in isolated trabecular

288 both cold tolerance and response to a beta3-adrenergic agonist were similar in both genotypes.

289 Additionally, contractile responses to alpha-adrenergic agonists were greatly attenuated.

290 Increasing doses of dobutamine, a beta1-adrenergic agonist, were administered to conscious unres

291 avenous injection of phenylephrine (an alpha-adrenergic agonist which raises blood pressure).

292 otropic and lusitropic tachyphylaxis to beta-adrenergic agonist, which likely contributes to its prot

293 extrarenal factors such as insulin and beta-adrenergic agonists, which stimulate the movement of K f

294 ogenous NO donor), and isoproterenol (a beta-adrenergic agonist whose vasodilator effect stems from t

295 y stimulation of isoproterenol (ISO), a beta-adrenergic agonist with a peak at approximately 12 hours

296 (3)(-)/CO(2), cholinergic agonists, and beta-adrenergic agonists, with or without selected inhibitors

297 Mice chronically fed a beta-adrenergic agonist without EE were protected from hippoc

298 e of whether regular use of an inhaled beta2-adrenergic agonist worsens airflow and clinical outcomes

299 and systemic administration of the alpha(2)-adrenergic agonist xylazine, all of which have been show

300 Alpha2-adrenergic agonists xylazine and clonidine were administ